DE2332840A1 - Alpha-sulfobenzylpenicillindiaminsalze und verfahren zu ihrer herstellung - Google Patents
Alpha-sulfobenzylpenicillindiaminsalze und verfahren zu ihrer herstellungInfo
- Publication number
- DE2332840A1 DE2332840A1 DE2332840A DE2332840A DE2332840A1 DE 2332840 A1 DE2332840 A1 DE 2332840A1 DE 2332840 A DE2332840 A DE 2332840A DE 2332840 A DE2332840 A DE 2332840A DE 2332840 A1 DE2332840 A1 DE 2332840A1
- Authority
- DE
- Germany
- Prior art keywords
- sulfobenzylpenicillin
- arginine
- salt
- lysine
- salts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims description 12
- -1 ALPHA-SULFOBENZYLPENICILLIN DIAMINE SALT Chemical class 0.000 title description 5
- 238000004519 manufacturing process Methods 0.000 title description 2
- 150000003839 salts Chemical class 0.000 claims description 30
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 23
- 239000004472 Lysine Substances 0.000 claims description 20
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 18
- 239000004475 Arginine Substances 0.000 claims description 17
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 17
- 235000009697 arginine Nutrition 0.000 claims description 17
- 235000018977 lysine Nutrition 0.000 claims description 17
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 16
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 12
- 150000001412 amines Chemical class 0.000 claims description 11
- 235000019766 L-Lysine Nutrition 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 3
- 229930064664 L-arginine Natural products 0.000 claims description 3
- 235000014852 L-arginine Nutrition 0.000 claims description 3
- 229960003121 arginine Drugs 0.000 description 14
- 239000007924 injection Substances 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 206010024769 Local reaction Diseases 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- JETQIUPBHQNHNZ-NJBDSQKTSA-N (2s,5r,6r)-3,3-dimethyl-7-oxo-6-[[(2r)-2-phenyl-2-sulfoacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical class C1([C@H](C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)S(O)(=O)=O)=CC=CC=C1 JETQIUPBHQNHNZ-NJBDSQKTSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 238000002329 infrared spectrum Methods 0.000 description 5
- 239000003456 ion exchange resin Substances 0.000 description 5
- 229920003303 ion-exchange polymer Polymers 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 229920001429 chelating resin Polymers 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 239000003589 local anesthetic agent Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 150000002960 penicillins Chemical class 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 150000003952 β-lactams Chemical class 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- RNHDAKUGFHSZEV-UHFFFAOYSA-N 1,4-dioxane;hydrate Chemical compound O.C1COCCO1 RNHDAKUGFHSZEV-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229920001577 copolymer Chemical compound 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- 210000003314 quadriceps muscle Anatomy 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6630172A JPS5512435B2 (enExample) | 1972-07-01 | 1972-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2332840A1 true DE2332840A1 (de) | 1974-01-17 |
Family
ID=13311838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2332840A Pending DE2332840A1 (de) | 1972-07-01 | 1973-06-28 | Alpha-sulfobenzylpenicillindiaminsalze und verfahren zu ihrer herstellung |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US3925357A (enExample) |
| JP (1) | JPS5512435B2 (enExample) |
| AT (1) | AT325206B (enExample) |
| AU (1) | AU469986B2 (enExample) |
| BE (1) | BE801588A (enExample) |
| CA (1) | CA996548A (enExample) |
| CH (1) | CH573435A5 (enExample) |
| CS (1) | CS168036B2 (enExample) |
| DE (1) | DE2332840A1 (enExample) |
| FR (1) | FR2190414B1 (enExample) |
| GB (1) | GB1386566A (enExample) |
| HU (1) | HU166029B (enExample) |
| NL (1) | NL7308048A (enExample) |
| PL (1) | PL92969B1 (enExample) |
| SE (1) | SE402916B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5522148U (enExample) * | 1978-07-29 | 1980-02-13 | ||
| EA007485B1 (ru) * | 2001-02-24 | 2006-10-27 | Берингер Ингельхайм Фарма Гмбх Унд Ко. Кг | Производные ксантина, способ их получения, фармацевтическая композиция на их основе и способ ее получения |
| US20030171424A1 (en) * | 2002-03-07 | 2003-09-11 | Lin Ai J. | Intravenous formulation of artelinic acid for treatment of severe and complicated malaria |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) * | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DE102005035891A1 (de) * | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| MX2008014024A (es) | 2006-05-04 | 2008-11-14 | Boehringer Ingelheim Int | Formas poliformas. |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| EP1852108A1 (en) * | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| EP3542801A1 (en) * | 2007-08-17 | 2019-09-25 | Boehringer Ingelheim International GmbH | Purin derivatives for use in the treatment of fap-related diseases |
| PE20140960A1 (es) * | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
| KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| CN103816158A (zh) * | 2008-08-15 | 2014-05-28 | 勃林格殷格翰国际有限公司 | 用于治疗fab-相关疾病的嘌呤衍生物 |
| CN102149407A (zh) | 2008-09-10 | 2011-08-10 | 贝林格尔.英格海姆国际有限公司 | 治疗糖尿病和相关病症的组合疗法 |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| CN107011345A (zh) | 2008-12-23 | 2017-08-04 | 勃林格殷格翰国际有限公司 | 有机化合物的盐形式 |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| EP2504002B1 (en) | 2009-11-27 | 2019-10-09 | Boehringer Ingelheim International GmbH | Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin |
| KR101927068B1 (ko) | 2010-05-05 | 2018-12-10 | 베링거 인겔하임 인터내셔날 게엠베하 | 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법 |
| KR20200028498A (ko) | 2010-06-24 | 2020-03-16 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| HUE061596T2 (hu) | 2011-07-15 | 2023-07-28 | Boehringer Ingelheim Int | Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| US20130303462A1 (en) | 2012-05-14 | 2013-11-14 | Boehringer Ingelheim International Gmbh | Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome |
| ES2929025T3 (es) | 2012-05-14 | 2022-11-24 | Boehringer Ingelheim Int | Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| BR112018072401A2 (pt) | 2016-06-10 | 2019-02-19 | Boehringer Ingelheim International Gmbh | combinações de linagliptina e metformina |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1026793A (fr) * | 1949-08-02 | 1953-05-04 | American Cyanamid Co | Procédé de préparation de sels de pénicilline |
| NL6803062A (enExample) * | 1967-03-10 | 1968-09-11 | ||
| US3557094A (en) * | 1968-01-05 | 1971-01-19 | Pfizer & Co C | Substituted alkyl esters of alpha-carboxy aryl penicillins |
| AT290728B (de) * | 1968-09-28 | 1971-05-15 | Takeda Chemical Industries Ltd | Verfahren zur herstellung neuer penicilline |
-
1972
- 1972-07-01 JP JP6630172A patent/JPS5512435B2/ja not_active Expired
-
1973
- 1973-06-01 HU HUTA1257A patent/HU166029B/hu unknown
- 1973-06-07 FR FR7320833A patent/FR2190414B1/fr not_active Expired
- 1973-06-08 NL NL7308048A patent/NL7308048A/xx not_active Application Discontinuation
- 1973-06-19 US US371528A patent/US3925357A/en not_active Expired - Lifetime
- 1973-06-25 CS CS4540A patent/CS168036B2/cs unknown
- 1973-06-28 BE BE132836A patent/BE801588A/xx unknown
- 1973-06-28 DE DE2332840A patent/DE2332840A1/de active Pending
- 1973-06-28 SE SE7309138A patent/SE402916B/xx unknown
- 1973-06-29 AT AT576473A patent/AT325206B/de not_active IP Right Cessation
- 1973-06-29 CH CH955873A patent/CH573435A5/xx not_active IP Right Cessation
- 1973-06-29 CA CA175,329A patent/CA996548A/en not_active Expired
- 1973-07-02 GB GB3147473A patent/GB1386566A/en not_active Expired
- 1973-07-02 PL PL1973163783A patent/PL92969B1/pl unknown
- 1973-07-02 AU AU57600/73A patent/AU469986B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| US3925357A (en) | 1975-12-09 |
| NL7308048A (enExample) | 1974-01-03 |
| CS168036B2 (enExample) | 1976-05-28 |
| BE801588A (fr) | 1973-12-28 |
| JPS5512435B2 (enExample) | 1980-04-02 |
| AU469986B2 (en) | 1976-02-26 |
| FR2190414A1 (enExample) | 1974-02-01 |
| FR2190414B1 (enExample) | 1976-07-02 |
| CA996548A (en) | 1976-09-07 |
| PL92969B1 (enExample) | 1977-04-30 |
| AU5760073A (en) | 1975-01-09 |
| HU166029B (enExample) | 1974-12-28 |
| JPS4925121A (enExample) | 1974-03-06 |
| AT325206B (de) | 1975-10-10 |
| SE402916B (sv) | 1978-07-24 |
| GB1386566A (en) | 1975-03-12 |
| CH573435A5 (enExample) | 1976-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2332840A1 (de) | Alpha-sulfobenzylpenicillindiaminsalze und verfahren zu ihrer herstellung | |
| DE2332878C2 (de) | Salze von Cephalosporinen mit Arginin und Lysin, ihre Herstellung und injizierbare pharmazeutische Zubereitungen | |
| DE2527914A1 (de) | Vincaminverbindungen, verfahren zu deren herstellung sowie diese enthaltende pharmazeutische mittel | |
| DE1811518B2 (de) | Daunorubicinderivale, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen | |
| DE2725246C2 (enExample) | ||
| AT354644B (de) | Verfahren zur herstellung von neuen salzen von alkaloidderivaten von thiophosphorsaeure | |
| DE814316C (de) | Verfahren zur Herstellung von Streptomycin- und Dihydrostreptomycinsalzen | |
| DE2166270C3 (de) | Nicotinoylaminoäthansulfonyl-2amino-thiazol | |
| DE951567C (de) | Verfahren zur Herstellung von Antibiotikappantothenaten | |
| DE2165200A1 (de) | Verfahren zur Herstellung der wasserfreien Form von 6- eckige Klammer auf D(-)-alpha-Aminopheny lacetamido eckige Klammer zu -penicilliansäure | |
| DE1941284C3 (de) | N hoch 1-L-Seryl-N hoch 2-(2,3,4trihydroxybenzyl)-hydrazld, Verfahren zu dessen Herstellung sowie dessen Säureadditionssalze und dieses enthaltende Arzneimittel | |
| DE951722C (de) | Verfahren zur Herstellung von (-)-3-Oxy-N-propargylmorphinan | |
| DE3418652C2 (enExample) | ||
| DE2257360C2 (de) | 1-(2-Chloräthyl)-1-nitroso-3-[(2-methyl-4-amino-pyrimidin-5-yl)methyl]harnstoff und Verfahren zu seiner Herstellung | |
| DE2164392A1 (de) | Verfahren zu der Herstellung von 5-(A-Aminobutyl)-hydantoin | |
| DE2235745C3 (de) | 2-Amino-2',6'-propionoxylidid. Verfahren zu dessen Herstellung und dieses enthaltende Arzneimittel | |
| DE1220421B (de) | Verfahren zur Herstellung von 2-Pyridinaldehyd-guanylhydrazonen | |
| AT300810B (de) | Verfahren zur Herstellung neuer Pyridoxinderivate | |
| DE1793309C3 (de) | Chloramphenicolsuccinatsalze basischer Aminosäuren | |
| DE1445538C (de) | 2 (2,6 Dibromphenyl)-amino 1,3 diazacyclopenten (2), dessen Saureadditions salze sowie Verfahren zu deren Herstellung | |
| DE2216627B2 (de) | 2,4,6-Trijodbenzoesäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Röntgenkontrastmittel | |
| DD290189A5 (de) | Verbessertes verfahren zur herstellung von 2-benzimidazol-carbaminsaeuremethylester | |
| AT228199B (de) | Verfahren zur Herstellung eines neuen Imidazolinderivates und seiner Salze | |
| DE1265754B (de) | Verfahren zur Herstellung von Salzen von substituierten 1, 8-Dihydro-1, 3, 6, 8-tetraazapyrenen | |
| DE895672C (de) | Insecticides und fungicides Pflanzenschutzmittel und Verfahren zu seiner Herstellung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHJ | Non-payment of the annual fee |